Retatrutide and Levothyroxine

Updated August 8, 2026

Retatrutide is an investigational medication in clinical trials. It is not FDA-approved, is not legally compoundable, and is not available through Trimi. Trimi does not offer it and has no plans to. This article is editorial safety coverage for people researching the drug-development pipeline.

This article is general information, not medical advice. Thyroid management depends on your labs, history, and full medication list. Consult a licensed clinician before making any medication decision, and change levothyroxine or any other prescription dosing only under clinician guidance.

Keep reading

Sources & References

Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. NEJM 2023. PubMed
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021. PubMed
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022. PubMed
U.S. Food and Drug Administration: Human Drug Compounding. FDA.gov
ClinicalTrials.gov, U.S. National Library of Medicine trial registry. ClinicalTrials.gov

Key Takeaways

Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by a 503A community sterile compounding pharmacy (BelieveRx, Texas State Board pharmacy license #35264). Compounded preparations are not FDA-approved as drugs, and FDA does not review them for safety, effectiveness or quality before marketing.
Eligibility for GLP-1 treatment is determined individually by a licensed clinician from your medical history, current medications and risk factors; Trimi does not publish a BMI cut-off. The branded semaglutide and tirzepatide labels list a personal or family history of medullary thyroid carcinoma or MEN 2 as contraindications, and your clinician also reviews history such as pancreatitis, gallbladder or kidney disease, and pregnancy plans.
Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Most are mild-to-moderate and concentrated during dose escalation. Severe gastrointestinal symptoms causing dehydration can increase acute kidney injury risk and should be reported to the prescribing clinician.
This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history.

TET

Written by Trimi Editorial Team

Trimi publishes this educational content. This byline does not imply a clinical review.

What real Trimi patients say

Verbatim quotes from Trimi's Facebook and Reddit community reviews. Quotes and source attribution are preserved.

Really great customer service! Fast shipment.

- Amy K.Facebook

Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

- Veronica L.Facebook

See all community reviews →

Editorial Standards

Trimi publishes patient education with dated updates for fast-changing pricing, access, and safety topics.

Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

Scientific References

Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

Was this article helpful?

Keep Reading

Comparisons